2bind GmbH Relaunches with Renewed Focus on Empowering Drug Discovery and Development through Biophysical Research Services.
May 2017 – 2bind GmbH today announces a corporate and strategic relaunch, marking a significant milestone and setting the stage for its future positioning as a leading provider of biophysical research services. Prof. Ralf Wagner – founder, CEO, and CSO of Geneart AG (1999-2012), a previously public BioTech company (now part of Thermofisher Inc.) – joins 2bind as new shareholder as well as business and strategic advisor.
„Inspired by our founder Prof. Gernot Längst, and now also supported by Prof. Wagner, jointly forming 2binds advisory board, 2bind will sharpen its focus on delivering high-quality research services and strengthen the R&D pipeline of our clients and customers in the biotech, pharmaceutical, and academic sectors“, states 2bind‘s CEO Dr. Thomas Schubert. „I am excited by the opportunity to help navigating 2bind‘s growth, addressing new market segments, and ensuring that researchers in industry and academia have global access to the most cutting-edge technologies and expertise to drive their projects forward.“ The company’s prowess in biophysical tools, techniques, and tailor-made assays will empower researchers to accelerate drug discovery and development across various stages, from hit identification to lead optimization. Prof. Längst adds: „This strategic realignment will enable 2bind to expand its portfolio of biophysical offerings in the future, carefully selecting a broader range of tools and instruments to meet the diverse needs of its clients”.
